Patient Advocates Rally Against New OMB Rule Targeting Their Voice

When the Office of Management and Budget released its latest rule last month, a handful of health‑focused nonprofits thought it would be just another bureaucratic footnote. Instead, they saw a possible chokehold on the very activity that keeps patients heard in Washington.

What emerged was a coordinated effort that now counts 57 patient‑advocacy organizations—ranging from rare‑disease societies to national cancer coalitions—pressing Congress to step in and block the regulation. Their joint letter, signed by more than a hundred senior leaders, reads like a plea and a warning rolled into one.

The rule, drafted under the Trump administration, tightens the definition of “political activity” for 501(c)(3) charities. In plain English, it means that many nonprofits could be forced to halt or dramatically scale back the lobbying and advocacy work that has long been their lifeblood.

“We’re not talking about partisan campaigning,” says Linda Martinez, executive director of the Heart Health Alliance. “We’re talking about telling lawmakers why a particular drug matters, why a screening program should be funded, why patients need better access. That’s core to our mission.”

Advocates argue the OMB’s interpretation runs contrary to long‑standing IRS guidance, which already allows a modest amount of lobbying as long as it’s not a substantial part of the organization’s activities. The new rule, however, would replace that nuanced approach with a blunt, one‑size‑fits‑all metric.

Critics fear the ripple effects could be severe: reduced research funding, slower adoption of life‑saving therapies, and a quieter voice for patients who depend on these groups to amplify their stories on Capitol Hill.

Congressional supporters have taken note. Several members of the House Energy and Commerce Committee have expressed concern, noting that the rule could undermine decades of progress in patient‑centered legislation.

“We need to protect the ability of nonprofits to speak truth to power,” said Rep. Maya Patel (D‑CA). “If we silence the advocates, we silence the patients.”

The coalition isn’t just waiting for a vote. They’re mobilizing grassroots supporters, filing comments with the Federal Register, and planning a series of town‑hall meetings to keep the pressure on.

At its core, the battle is about a simple question: should a government rule be able to silence the very people it exists to serve? For the 57 groups united in this effort, the answer is a resounding no.